Evidence map›Paper›PMID 41394556›Full record

ArticlebioRxiv : the preprint server for biology2025

Blood-based Transcriptomics Reveal Sex- and Amyloid-Modulated Biology of Plasma pTau217 in Preclinical Alzheimer's Disease.

Mabel Seto, Hannah M Klinger, Michelle Clifton, Vaibhav A Janve, Jane A Brown, Colin Birkenbihl, Gillian Coughlan, Diana L Townsend, Ting-Chen Wang, Michael Properzi and 13 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Mabel SetoMassachusetts General Hospital/Harvard Medical School, Boston, MA.
Hannah M KlingerMassachusetts General Hospital/Harvard Medical School, Boston, MA.
Michelle CliftonVanderbilt Memory & Alzheimer's Center, Vanderbilt University Medical Center, Nashville, TN.
Vaibhav A JanveVanderbilt Memory & Alzheimer's Center, Vanderbilt University Medical Center, Nashville, TN.
Jane A BrownMassachusetts General Hospital/Harvard Medical School, Boston, MA.
Colin BirkenbihlMassachusetts General Hospital/Harvard Medical School, Boston, MA.
Gillian CoughlanMassachusetts General Hospital/Harvard Medical School, Boston, MA.
Diana L TownsendMassachusetts General Hospital/Harvard Medical School, Boston, MA.
Ting-Chen WangVanderbilt Memory & Alzheimer's Center, Vanderbilt University Medical Center, Nashville, TN.
Michael ProperziMassachusetts General Hospital/Harvard Medical School, Boston, MA.
Bernard HanseeuwMassachusetts General Hospital/Harvard Medical School, Boston, MA.
Jasmeer ChhatwalMassachusetts General Hospital/Harvard Medical School, Boston, MA.ORCID 0000-0002-7792-1698
Hyun-Sik YangBrigham and Women's Hospital, Boston, MA.ORCID 0000-0002-8318-0443
Robert A RissmanAlzheimer's Therapeutic Research Institute, Keck School of Medicine of the University of Southern California, San Diego, CA.ORCID 0000-0001-9245-8278
Paul AisenAlzheimer's Therapeutic Research Institute, Keck School of Medicine of the University of Southern California, San Diego, CA.
Madison CuppelsMassachusetts General Hospital/Harvard Medical School, Boston, MA.
Michael C DonohueAlzheimer's Therapeutic Research Institute, Keck School of Medicine of the University of Southern California, San Diego, CA.
Rema RamanAlzheimer's Therapeutic Research Institute, Keck School of Medicine of the University of Southern California, San Diego, CA.
Keith A JohnsonMassachusetts General Hospital/Harvard Medical School, Boston, MA.
Reisa A SperlingMassachusetts General Hospital/Harvard Medical School, Boston, MA.
Logan DumitrescuVanderbilt Memory & Alzheimer's Center, Vanderbilt University Medical Center, Nashville, TN.
Timothy J HohmanVanderbilt Memory & Alzheimer's Center, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-3377-7014
Rachel F BuckleyMassachusetts General Hospital/Harvard Medical School, Boston, MA.ORCID 0000-0002-5356-5537

Funding

RECRUITMENT COREU19AG010483 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FELDMAN, HOWARD · 2013 to 2020
$80.6M
API A4 Alzheimer's Prevention TrialR01AG058468 · NIA · BANNER HEALTH · PI AISEN, PAUL S., ALEXANDER, ROBERT C · 2018 to 2025
$31.9M
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension StudyR01AG063689 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI AISEN, PAUL S., SPERLING, REISA A. · 2019 to 2024
$30.8M
USCADRC Diversity Supplement PachicanoP30AG066530 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HELENA Chang CHUI, ARTHUR W TOGA · 2020 to 2026
$27.8M
The inactive X: discovering sex genes that influence female vulnerability to Alzheimer's diseaseDP2AG082342 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Rachel Frances Buckley · 2022 to 2026
$2.5M
NIA NIH HHS DP2 AG082342NIA NIH HHS P30 AG066530NIA NIH HHS R01 AG058468NIA NIH HHS R01 AG063689NIA NIH HHS U19 AG010483
6 · The paper itself

Abstract

Plasma pTau217, an emerging Alzheimer's disease (AD) biomarker, may reflect a synaptic response to β-amyloid (Aβ) plaques before cortical tangle formation, but the broader biological processes at play remain unclear. Using whole blood RNAseq, we sought to identify gene expression associated with plasma pTau217 and to determine whether

Identifiers

PMID41394556
PMCPMC12697722

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.